Incepta pharmaceuticals Ltd, one of the leading pharmaceutical company in Bangladesh, is now manufacturing three monoclonal antibodies for the treatment of Osteoporosis, Rheumatoid Arthritis, Psoriasis, Spondylitis, Inflammatory Bowel Disease, Non Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia etc. Since its inception, Incepta has always pioneered in launching many first ever manufactured drugs in Bangladesh market. To continue its legacy, Incepta has launched 3 mAbs with brand name Relyto 100 & 500 (Rituximab), Denosis 60 & 120 (Denosumab) and Advixa (Adalimumab). True to its vision to become a trusted healthcare company that provides better health for everyone, everywhere, Incepta has launched these drugs to ensure better health for thousands of patients suffering from disease conditions like Osteoporosis, Arthritis, and Spondylitis etc.
Osteoporosis is a medical condition in which the bones become brittle and fragile from loss of tissue, typically as a result of hormonal changes, or deficiency of Calcium or vitamin D. Rheumatoid Arthritis is a chronic progressive disease causing inflammation in the joints and resulting in painful deformity and immobility, especially in the fingers, wrists, feet, and ankles. Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body's immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues (such as the spleen and bone marrow) whereas chronic lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets. Thousands of patients are suffering from these debilitating diseases. Quality of life is significantly hampered, even the simplest tasks like drinking a glass of water becomes difficult. It is to be noted that Adalimumab is the best-selling drug in the world. Millions of patients worldwide are taking this mAbs for conditions like Rheumatoid Arthritis, Psoriasis, Spondylitis, Inflammatory Bowel Diseases etc. Denosumab is used for Osteoporosis and to reduce bone fracture risk in those who have risk factors. Relyto is used for Non Hodgkin’s lymphoma and chronic lymphocytic leukemia.
Incepta pharmaceuticals will continue to launch newer and better drug for the betterment of patients. Its pipeline includes many anticancer drugs including many mAbs and Tinibs. These drugs are known as targeted therapy for cancer. There are about 15 lakh cancer patients in Bangladesh, where about 2 lakh patients newly adding every year in this pool. In the coming years, the increase in population and longevity will result in an increase in the number of cancer patients in Bangladesh. With the launching of all these drugs Incepta hope to achieve new frontiers in cancer treatment regimen.
Incepta Vaccine Ltd has developed an international standard bulk manufacturing facility providing the best environmental condition for performing the operations. The facility can manufacture both Bacterial and Viral bulk antigens. These will make us less dependent on vaccine import and help us to become a self-sufficient vaccine manufacturing country.
Addressing the inaugural ceremony, the minister said that Bangladesh is now able to export quality medicines to 90 countries all over the globe. Bangladesh is now capable of manufacturing life saving vaccine and successfully reduces the dependency on imported vaccines. ‘We will take the initiatives to get the WHO authorization which is needed for export of vaccines.’ The minister said.
Director General of Drug Administration, Major General Md Mustafizur Rahman and Secretary General of Bangladesh Association of Pharmaceutical Industries, SM Shafiuzzaman were also present there as special guests.
Twinvir is mainly indicated for the treatment of Hepatitis C genotype 1/4/6 infection. With this treatment option there is no need of either Interferon or Ribavirin. One tablet once a day is sufficient for the treatment of Hepatitis C. Twinvir provides high cure rate, less daily tablet burden, less complicated treatment regimens and also more affordable to the patients.
In addition to local market, Incepta hopes to launch this product to international market in near future.
Previously, treatment of Hepatitis C was limited to Interferon alfa only. It is an injectable drug and thus is associated with many limitations such low efficacy rate, patients incompliance, side effects, high costs etc. With the launching of Sofosbuvir these limitations have now been minimized to a great extant. Sofosbuvir tablet shows greater than 90% efficacy rate, being an oral drug patient compliance has improved and it is now more affordable treatment option.
Incepta pharmaceuticals have launched this generic at almost 99% discount price of the innovator’s drug. Initially Incepta launched this drug in Bangladesh market. To date very few well controlled studies have been performed regarding the prevalence of hepatitis C in Bangladesh. In these studies 0.8-1% people of total population has been found to be carriers of hepatitis C virus.
Globally more than 170 million people are infected with the fatal disease hepatitis C. In near future the company aims to sell the drug overseas, including parts of Southeast Asia and Africa. Bloomberg has reported that the World Health Organization (WHO) is considering reviewing Hopetavir under its prequalification program, which could make the drug available in countries where innovator brand lacks patent protection and to humanitarian groups such as Médecins Sans Frontières (MSF).
In his speech, honorable Minister of Health & Family Welfare Prof. Dr. A. F. M. Ruhal Haque said “I am appreciating such initiative of Incepta Vaccine Ltd. At present our Government needs to spend several hundred crore Taka to import the necessary vaccines for EPI program. But, now we can save huge amount of foreign currency for such initiative of Incepta Vaccine Ltd.” Honorable Minister also visited the newly constructed 3 stored vaccine facilities which consist of 75000 square-feet, animal house which is required to ensure the efficacy of manufactured vaccines and also cold chain system which is important to maintain the efficacy of vaccine. He appreciated much to see such a world class vaccine plant and its facilities.
National Professor M. R. Khan said “Incepta has been supplying medicine of supreme quality from its inception. Their initiative makes a remarkable appreciation to reduce the dependency on foreign medicine.”
Abdul Muktadir, Managing Director of Incepta Vaccine Ltd said “in the near past we had to import essential vaccines from foreign countries. But now we are manufacturing vaccines in our own country. We have constructed a totally new and enormous vaccine plant according to the guidelines of WHO GMP.” He also said “the annual production capacity of our vaccine plant is about 18 crore vials which will not only fulfill the annual demand of EPI program but also provide us the opportunity to export these vaccines in the foreign countries.”
In conclusion, Mr. Muktadir promised to make all these high-tech and life saving vaccines available and affordable for the people of our country and sought overall assistance from the Government of Bangladesh for such endeavor.
Incepta Vaccine Ltd is the first Human vaccine company in Bangladesh, developed with primary objective to provide preventive medicine to vast majority of population at an affordable price. It is a new state of the art facility to manufacture vaccine in Bangladesh for the first time. The facility is fully compliant with WHO GMP guidelines. It has the following unique features:
• Four German filling lines, independent of each other so that four different products can be manufactured simultaneously. Each area has dedicated HVAC system to prevent cross contamination. All the filling area rooms are equipped with terminal HEPA filters, with required air changes so as to create Class A, B, C & D environment, as the requirement of GMP. Each filling line has a sterilizing autoclave and decontamination autoclave. Each line is connected to independent visual inspection and labeling machine so as to prevent the chances of cross contamination
• It has an advanced fully GMP compliant R&D facility which can independently handle several projects simultaneously involving bacteria and virus.
• It has well equipped microbiology and chemical laboratory.
• It also has a large lab animal house covering around 24,000 square feet area which has bio safety level 2 standard lab for testing of various vaccines which involve challenge with infectious organisms.
• It has unique cold chain system to maintain the required temperature in every step of filling to packaging. It has well designed spacious cold rooms to store raw materials and finished products. It has 4 cold rooms of temperature within 2-8 °C and 2 cold rooms of temperature -20 °C to store raw materials and finished products.
Incepta Vaccine Ltd can produce any dose size from 0.1ml to 15 ml, with 4 different products simultaneously and has capacity to fill more than 2,40,000 ampoules and 3,60,000 vials per day. The yearly capacity is 180 million vials and ampoules. To conduct the immunization program of EPI, yearly demand of vaccine is 21 million vials and other than EPI yearly demand is 10 million vials which is increasing day by day. The production capacity of this facility is enough to meet the local demand and export.
Incepta Vaccine Ltd is now manufacturing and marketing Typhoid vaccine (Vaxphoid), Rabies vaccine (Rabix-vc) and Tetanus vaccine (Vexitet). In near future Hepatitis B, Polio, Measles, Rubella, Tetanus antitoxin, Rabies immunoglobulin, Pentavalent and all other necessary vaccines will be manufactured. Incepta Vaccine Ltd is committed to provide all high tech life saving vaccines to the people at affordable price.
Incepta Vaccine Ltd is the first Human vaccine company in Bangladesh, developed with primary objective to provide preventive medicine to vast majority of population at an affordable price. It is a new state of the art facility to manufacture vaccine in Bangladesh for the first time. The facility is fully compliant with WHO GMP guidelines. It has an advanced fully GMP compliant R&D facility which can independently handle several projects simultaneously involving bacteria and virus. Incepta has well equipped microbiology and chemical laboratory, a large lab animal house covering around 24,000 square feet area which has bio safety level 2 standard for testing of various vaccines.
Incepta has unique cold chain system to maintain the required temperature in every step of filling to packaging. It has well designed spacious several cold rooms to store raw materials and finished products. It has 4 cold rooms of temperature within 2-8 °C and 2 cold rooms of temperature -20 °C to store raw materials and finished products.
In near future, Rabies, Tetanus, Hepatitis B, Polio, Measles, Rubella, Tetanus antitoxin, Rabies immunoglobulin, Pentavalent and all other necessary vaccines will be manufactured. Incepta Vaccine Ltd is committed to provide all high tech life saving vaccines to the people of Bangladesh at affordable price.
The achievements of Pharmaceutical industry in last few years are undoubtedly praise worthy. On this succession accreditation with European GMP (Good Manufacturing Practice) certification by Incepta Pharmaceuticals Ltd. will create a new era in exporting pharmaceutical products. Dr. A M M Shawkat Ali, Honorable advisor, Ministry of Health and Family Welfare and Ministry of Food and Disaster Management, addressed this on a program organized by Incepta Pharmaceuticals Ltd. on 14th March at Hotel Sonargaon on the occasion of receiving European GMP (Good Manufacturing Practice) certification. The pharmaceutical industry has created tremendous potentiality to earn foreign currency, he added. He assured all the possible assistances from the Government to add muscle in this particular sector.
The program started with the welcome speech of Mr. Abdul Muktadir, Managing Director of Incepta Pharmaceuticals Ltd. Besides Mr. Charles Whitley, Charge D Affairs of European Commission, Brig. Gen. Sarker M A Matin, Director, Directorate of Drug Administration, Mr. S M Shafiuzzaman, President, Bangladesh Association of Pharmaceuticals Industries, Austrian pharmaceutical marketing specialist Mr. Joerg Kloppert also delivered their speech.
According to Mr. Abdul Muktadir, Incepta has earned remarkable goodwill both home and abroad in manufacturing high quality medicine. On this succession the achievement of this GMP certificate from European Commission has created new possibilities. The respect and position of local pharmaceutical industry will enhance to a great extent internationally by this achievement and the scope of exporting will be higher than ever before. Entrepreneurs and top management of many Pharma companies, renowned physicians, reputed pharmacists, representatives of foreign embassies, and civil society were also present in the evening.
To mention, by exporting in 19 countries, Incepta is not only bringing fame for the country, but also contributing remarkably in the development of national economy by earning foreign remittance. Incepta Pharmaceuticals Ltd. received accreditation with the European GMP certification on 11th January this year which will allow the company to export in all the countries of European Union and this certification is first ever for any local company.
Later on the envoy went around the production area of the plant while she was briefed by the Director Technical Operations Mr. Mahbubul Karim on international standard manufacturing facilities including quality management systems of the factory. The envoy expressed her satisfaction on observing the infrastructure and facilities. In her short opinion to the press personnel she also hoped about Incepta's successful contribution in export.
During the program, all other Directors of Incepta Pharmaceuticals Limited were also present.
US Deputy Chief of Mission to Bangladesh, Ms. Judith A. Chammas being given a memento by Incepta Pharmaceuticals Limited Managing Director Abdul Muktadir during her visit to the factory on Monday, May 8, 2006
Diplomats, business leaders and magnates, entrepreneurs, intellectuals, professionals and government officials attended the function.rnrnAs the names of award winners were announced one by one amid pin-drop silence, the audience burst into applause congratulating the business heroes. Two giant screens displayed their exemplary successes in brief.rnrnReceiving the Enterprise of the Year 2004 Award on behalf of Incepta Pharmaceuticals Ltd, its Managing Director Abdul Muktadir said his company is a research-based pharmaceuticals company and has achieved unprecedented growth in the recent years.rnrnExpressing her reaction to winning the Outstanding Woman in Business of the Year 2004 Award, Agroconcern Proprietor Selina Quader said it was the first recognition of her endeavours. She was sure the award would encourage more women to enter the world of business. rnrn"I started my business with a capital of only Tk 5,000, which by now has grown to Tk 20 million," she told the gala event.rnrnAfter receiving the Special Achievement Award on behalf of Unilever Bangladesh Limited, its Chairman and MD Sanjiv Mehta said his company is the second best performer in entire Asia. Mehta said his company has proved that business can grow in Bangladesh with ethical practices.rnrnUnilever has delivered a sustained double-digit growth at an average of nearly three times the country's GDP growth for the last six years, he told the function, and expressed his conviction that Bangladeshi enterprises can manufacture world-class products. rnrnKazi Farms Group MD Kazi Zahedul Hasan, who was awarded as the Business Person of the Year 2004, said his company deals with around 60,000 farmers of the country. He said, "We recently have started exporting hatching eggs to Saudi Arabia, thereby adding a new item in the country's export basket."
Earlier, The Daily Star Editor Mahfuz Anam observed that a silent revolution has taken place in Bangladesh led by the entrepreneurs who are creating wealth for the nation. "It's a tremendous success of our entrepreneurs that they have uplifted the country's image by popularising products bearing the seal 'Made in Bangladesh' in the global market. So, they do deserve recognition," he told the gathering. rnrnIn his speech, DHL Worldwide Express, Bangladesh Country Manager Desmond Quiah said the success the awardees have achieved in taking their enterprises to a new height proves that they see more than others do.
Technical Director of Incepta Pharmaceuticals Ltd. Mr. Mahbubul Karim delivered speech on factory infrastructure and technical facilities to the distinguished guests. Managing Director of Incepta Pharmaceuticals Ltd. Mr. Abdul Muktadir pointed out chronology of Pharmaceutical Industry of Bangladesh and future prospects of medicine export. After presentation, Saudi delegates inspected the manufacturing area and quality control facilities of the black dresses for prom factory. Saudi health minister Dr. Hamad Bin Abdullah Al-Manea and other guests expressed their satisfaction on the present infrastructure of the factory. Concerned experts hope that Incepta Pharmaceutical Ltd. will contribute significantly in the export of medicine from Bangladesh. rnrnIn this occasion, Managing Director of Incepta Pharmaceuticals Ltd. presented crests and gifts to the honorable guests. Saudi high official delegates led by honorable Health Minister of Saudi Arabia Dr. Hamad Bin Abdullah Al-Manae came to Bangladesh on 18th September for an official visit. The guests visited Incepta and another national pharmaceutical industry at this time. Incepta Pharmaceuticals Ltd. is one of the leading pharmaceutical manufacturers in Bangladesh.